1.A Case of Idiopathic Acute Pancreatitis in the First Trimester of Pregnancy.
Hara T1, Kanasaki H1, Oride A1, Ishihara T1, Kyo S1. Case Rep Obstet Gynecol. 2015;2015:469527. doi: 10.1155/2015/469527. Epub 2015 Dec 30.
Acute pancreatitis is rare in pregnancy, with an estimated incidence of approximately 1 in 1000 to 1 in 10,000 pregnancies. Acute pancreatitis in pregnancy usually occurs in the third trimester. Here, we report a case of acute pancreatitis in the first trimester. A 36-year-old primigravida at 11 weeks of gestation complained of severe lower abdominal pain. The pain gradually worsened and migrated toward the epigastric region. She had no history of chronic alcoholism. Blood investigations showed elevated level of C-reactive protein (9.58 mg/dL), pancreatic amylase (170 IU/L), and lipase (332 IU/L). There was no gallstone and no abnormality in the pancreatic and biliary ducts on ultrasonography. Antinuclear antibody and IgG4 were negative and no evidence of hyperlipidemia or diabetes was found. There was also no evidence of viral infection. On the third day of hospitalization, she was diagnosed with severe acute pancreatitis on magnetic resonance imaging.
2.Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin.
Lim JY1, Kim JB1, Choo SJ1, Chung CH1, Lee JW1, Jung SH2. Ann Thorac Surg. 2016 Apr 12. pii: S0003-4975(16)00056-4. doi: 10.1016/j.athoracsur.2016.01.044. [Epub ahead of print]
BACKGROUND: Heparin is the main anticoagulant used during extracorporeal membrane oxygenation (ECMO) support. Nafamostat mesilate, a synthetic serine protease inhibitor, has seen increased use as a substitute for heparin in patients undergoing ECMO because of its short half-life. We aimed to compare these 2 anticoagulants with respect to bleeding and thromboembolic complications during ECMO support.
3.Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy.
Makino S1, Egi M1, Kita H2, Miyatake Y3, Kubota K1, Mizobuchi S4. Int J Artif Organs. 2016 Feb 25;39(1):16-21. doi: 10.5301/ijao.5000465. Epub 2016 Feb 9.
PURPOSE: Nafamostat mesilate (NM) can be used as a regional anticoagulant for continuous renal replacement therapy (CRRT). The primary aim of this study was to assess the association of the use of NM with risk of bleeding complications and compare it with the use of unfractionated heparin (UFH).
4.Nafamostat Mesilate Improves Function Recovery after Stroke by Inhibiting Neuroinflammation in Rats.
Li C1, Wang J1, Fang Y1, Liu Y1, Chen T1, Sun H1, Zhou XF2, Liao H3. Brain Behav Immun. 2016 Mar 23. pii: S0889-1591(16)30063-0. doi: 10.1016/j.bbi.2016.03.019. [Epub ahead of print]
Inflammation plays an important role in stroke pathology, making it a promising target for stroke intervention. Nafamostat mesilate (NM), a wide-spectrum serine protease inhibitor, is commonly used for treating inflammatory diseases, such as pancreatitis. However, its effect on neuroinflammation after stroke was unknown. Hence, the effects of NM on the inflammatory response post stroke were characterized. After transient middle cerebral artery occlusion (tMCAO) in rats, NM reduced the infarct size, improved behavioral functions, decreased the expression of proinflammatory mediators (TNF-α, IL-1β, iNOS and COX-2) in a time-dependent manner and promoted the expression of different anti-inflammatory factors (CD206, TGF-β, IL-10 and IL-4) at different time points. Furthermore, NM could inhibit the expression of proinflammatory mediators and promote anti-inflammatory mediators expression in rat primary microglia following exposure to thrombin combined with oxygen-glucose deprivation (OGD).
